Multiple myeloma: therapeutic delivery of antibodies and aptamers

Neret Pujol-Navarro, Mohammed M Al Qaraghuli, Karina Kubiak-Ossowska, Manal M Alsaadi, Gillian A Horne, Richard L Soutar, Elpiniki Paspali, Valerie A Ferro, Mark TS Williams, Paul A Mulheran

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)
45 Downloads (Pure)


Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.
Original languageEnglish
Pages (from-to)705-722
Number of pages18
JournalTherapeutic Delivery
Issue number10
Early online date27 Sept 2021
Publication statusPublished - 31 Oct 2021


  • review
  • antibody–drug conjugates
  • antibody therapy
  • aptamer–drug conjugates
  • aptamer therapy
  • molecular docking
  • multiple myeloma
  • nanoparticles


Dive into the research topics of 'Multiple myeloma: therapeutic delivery of antibodies and aptamers'. Together they form a unique fingerprint.

Cite this